Novo Nordisk shares tumble as data on weight-loss drug trial disappoints
Obesity treatment CagriSema misses goal of 25% reduction in body weight
Nordisk
since
auto-detected in 451 stories
4 months ago
The battle over the trillion-dollar weight-loss bonanza
Novo Nordisk and Eli Lilly are making blockbuster drugs. Can they maintain their lead?
Competition will make weight-loss drugs better, cheaper and bigger
Novo Nordisk and Eli Lilly face a growing number of challengers
|← first ← previous page 5 of 5